Cost-effectiveness analysis of first-line tislelizumab plus chemotherapy for recurrent or metastatic nasopharyngeal cancer.

Front Pharmacol · 2023 · PMC10642263 · PMID 37964872

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

Probabilistic sensitivity analysis demonstrated a clear trend toward tislelizumab plus chemotherapy yielding better cost-effectiveness outcomes with a 98.4%–99.3% chance of being cost-effective.

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.